CeriBell (NASDAQ:CBLL) Posts Quarterly Earnings Results, Misses Estimates By $1.03 EPS

CeriBell (NASDAQ:CBLL) announced its quarterly earnings results on Tuesday. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03), Zacks reports. The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million.

CeriBell Price Performance

Shares of NASDAQ:CBLL traded up $0.64 during midday trading on Thursday, reaching $28.52. 23,296 shares of the company’s stock were exchanged, compared to its average volume of 227,971. CeriBell has a fifty-two week low of $23.00 and a fifty-two week high of $29.53.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CBLL. Bank of America assumed coverage on CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price on the stock. William Blair started coverage on CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. Canaccord Genuity Group initiated coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, TD Cowen initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $31.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $31.20.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.